Gov. Wes Moore on LinkedIn: This afternoon, I joined President Joe Biden and Vice President Kamala… | 151 comments (2024)

My Washington Post welcome interview!"One lesson is to make sure that there’s a strong consumer voice in the crafting of health-care policy. Patients and the public are sometimes left out of these discussions, but they are the point of the health-care system and should be at the center of the conversation.""We need to be very clear that our health care is on the ballot. There are stark differences on health care that we need to hear from our policymakers on, whether it’s reproductive health, the ACA and its future, the [expanded tax credits] or prescription drug prices. On prescription drug prices, we could see [the federal government] either expanding both the number of drugs that we negotiate over and having those discounted prices be extended to a much broader set of payers and patients. Or we could see that power be repealed. In terms of the ACA, it’s not just the5 millionpeople who could lose coverage under the expiration of those subsidies. It’s the20 million-plus folks that might lose coverage under a total repeal … [which would bring on] spiking premiums leading the market into a death spiral."

143

2 Comments

Elective feticide is risky enough with the supervision of a medical professional.

2

Louisiana's governor on May 24 signed a bill making his state the first in the U.S. toclassify two abortion-inducing medicationsas controlled substances, a category that healthcare regulators typically reserve for drugs prone to abuse or addiction.The new law designates mifepristone and misoprostol, which the FDA approved more than two decades ago as safe and effective for terminating pregnancies, as Schedule IV drugs, typically pain-killers and mood-altering medications that merit greater oversight due to their potential for abuse or dependence.The measure, thrusting Republican-led efforts to restrict abortion back to the political forefront in a presidential election year, was signed into law by Republican Governor Jeff Landry a day after the state legislature sent it to his desk.The bill cleared Louisiana's Republican-majority House of Representatives and Senate by wide margins, even as efforts by the U.S. Food and Drug Administration to expand access to abortion pills is facing a legal challenge before the Supreme Court.Find out more: https://reut.rs/4bw0w1t

2

1 Comment

The latest from 340B Report:Missouri GOP Lawmaker Slams State AG’s ‘Irresponsible’ Claims Linking 340B Bill to Abortion As Governor’s Decision Looms -https://lnkd.in/e76zdh6ySupreme Court ‘Chevron’ Ruling Increases Pressure on Congress to Act on 340B But Unlikely to Immediately Impact Program Oversight - https://lnkd.in/eHTDEznWPatient Turned Advocate: David Alexander Discusses 340B - https://lnkd.in/eeiV4ixqViatris Becomes 37th Manufacturer to Place Restrictions on 340B Contract Pharmacy Use; Policy Applies to Hospitals and Health Centers - https://lnkd.in/e_9CUGpkMore Drugmakers Exempt States from Contract Pharmacy Restrictions as Four New State Laws Take Effect - https://lnkd.in/eqDtqGyMDelaware Legislature Passes Anti-Discrimination Protections for 340B Providers from PBMs but Drug Manufacturer Restrictions Remain - https://lnkd.in/ePr88ZWdHospital Groups Urge Federal Court to Uphold Maryland’s 340B Contract Pharmacy Access Law - https://lnkd.in/eGTVa5MwHospitals in Texas and Other States Sue HHS Over DSH Calculation Changes That Impact 340B Eligibility - https://lnkd.in/eu6mueK8Verity Panel Discussion: 340B Outlook from Washington, D.C. & the States - https://lnkd.in/e6MxBgJvTo get full access to 340B Report news reporting and analysis,visit https://lnkd.in/gJd7qNyg#340B #pharmacy #drugpricing #hospitals #hospitalpharmacy

7

2 Comments

"Unnecessary restrictions on access to mifepristone...will impose on women much higher risks of experiencing medical complications, prolonged economic hardship, and even death....These harms will particularly and disproportionately affect our most vulnerable, including Black and indigenous women, low-income women, and women living in rural areas."Last week, we filed an amicus brief with the Supreme Court in Food and Drug Administration (FDA) v. Alliance for Hippocratic Medicine, urging reversal of the decision by the Fifth Circuit Court of Appeals revoking FDA approval of mifepristone.We are wholly against the usurping of abortion access and reproductive decisions from the hands of individuals, their families, and their health care providers.Read the full brief here: 👉👉👉 https://lnkd.in/eY6Yc_Ps.#promotingwomenlawyers #reproductivejustice #healthcareequity #reproductiverights #womenshealthcareishealthcare

15

2 Comments

On March 26, the US Supreme Court is hearing oral arguments in a case that could dramatically reshape the abortion access landscape—again. Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration (FDA) is a groundless lawsuit targeting mifepristone, one of two drugs used in the most common abortion method in the US. Let’s be clear: Access to mifepristone is unchanged for now until the Court issues a decision. As our analysis explains, SCOTUS’s only reasonable option in this case is maintaining full access to this critical drug. Whether you've been following the case since the beginning or it’s new to you, our latest analysis breaks down the 8 key points you need to know. 📢 https://gu.tt/49Jw5E0

79

2 Comments

Abortion care is health care.

As medical professionals, it is our duty to educate the legal community on the intricacies of emergency abortion and the complications that arise when clinical care is denied to patients. Recently, the potential reversal of Roe V Wade has brought this issue to the forefront. That's why I voluntarily presented our new scoring system to help non-medical professionals make informed decisions when it comes to providing or denying care. Our goal is to clear the clutter and ensure that patients receive the care they need.https://lnkd.in/dx4rKF5k

This The Hill article from back in September reads that "Congress is under the gun on must-pass health bills":https://lnkd.in/gdj_wxJSIs that so?There is a vast gap between our aspirations for #healthcare legislation vs what is actually passed.Midway through its term, the current 118th Congress is on track to be one of the least productive on healthcare issues. So far, only ONE bill has passed both chambers of congress to become US law overall all of 2023! ("Securing the U.S. Organ Procurement and Transplantation Network Act")Don't believe me? Look for yourself:https://lnkd.in/gQJPd5EnTo give you a sense of how how difficult it is to pass healthcare legislation, in the prior 117th congress only 19 of 2275 bills introduced became law. That translates to 0.8%. And that was when BOTH chambers were controlled by Democrats who care about healthcare!To be fair, these numbers may not paint a 100% accurate picture. For some reason, the #inflationreductionact does not show up under the "health" filter for the 117th congress, even though it had pretty important healthcare-related provisions.A search for "prescription drug pricing" shows ~13 bills have been introduced since the beginning of the year:https://lnkd.in/geDSxTKd#biopharma leaders need to be aware of what is -- and is not -- happening in Washington DC, and choose their battles wisely. Some of these bills would surely hurt #biotechinnovation and patients alike, while others may make good sense.

1

Where Kamala Harris stands on three key pharma issuesHarris has shown support for drug pricing reform and took a hard line in several suits against pharma companies during her tenure as attorney general in California. Here’s what Harris’ record reveal about where she stands on three important issues:- Medicare drug price negotiations - Harris played a pivotal role in the Biden Administration passing the Inflation Reduction Act- Out-of-pocket costs - The IRA also created new out-of-pocket caps for seniors on Medicare Part D plans. In May, she said she intended to expand cost caps beyond Medicare recipients- Abortion and women’s health - Harris has made herself a central figure in the fight for women’s healthcare and abortion access, including abortion medication. More at: https://lnkd.in/dueEK8zJ#KamalaHarris #USAelection #pharmaindustry #biotech

17

2 Comments